A Phase 2 interventional study of APX001 in Candidemia, sponsored by Basilea Pharmaceutica. Completed at 29 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Basilea Pharmaceutica · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Candidemia with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Candidemia · United States.
Among the 33 studies in Candidemia with a site in United States, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 26th registered.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
Browse Candidemia studies →2 of the 33 studies in Candidemia with a site in United States are open now. Recruiting first, the newest first:
Basilea Pharmaceutica · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Augusta University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 63 across 44 interventional studies indexed under Candidemia.
Median enrollment 70 across the 27 interventional studies, 188 across the 6 observational. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Basilea Pharmaceutica has 3 studies filed under Candidemia — fewer than ten, so there is no comparison to draw.
1 of the studies in Candidemia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06907992Augusta UniversityA Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies in Candidemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy and safety of APX001 for the first-line treatment for candidemia including suspected or confirmed antifungal-resistant candidemia in non-neutropenic patients 18 yeas of age and older.
Suspicion of antifungal-resistant candidemia is sufficient (documented resistance is not required for enrollment). The Study Drug Treatment Period of APX001 will be a maximum of 14 days. After completion of 14 days study drug therapy, if further antifungal treatment is indicated to complete treatment of candidemia in accordance with standard practice guidelines, fluconazole (unless susceptibility results warrant alternative antifungal therapy) may commence for up to a further 7 days. There will be a Follow up Period of 4 weeks (+4 days) after EOT. The total duration of participation in the study is up to approximately 7.5 weeks.
This study will be conducted at approximately 20 sites in the United States and globally.
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: APX001
APX001
Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC)
Treatment Success is defined as meeting all of the following criteria: Two consecutive blood cultures negative for Candida spp. Alive at EOST No concomitant use of any other systemic antifungal therapies through end of study treatment
Time frame: One to forty-two days
Time to First Negative Blood Culture
Time to first negative blood culture was defined as the number of days from first dose date of study drug to the date of first post-Baseline negative blood culture + 1. Patients without a negative blood culture at post-Baseline visits were censored at the last assessment date.
Time frame: One to forty-nine days
Percentage of Patients With Mycological Outcomes at End of Study Treatment (EOST), End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)
Time frame: End of study treatment (EOST), end of treatment (EOT), and 2 and 4 weeks after end of treatment (EOT)
Percentage of Patients With Treatment Success at End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT)
Time frame: 2 and 4 weeks after end of treatment (EOT)
Overall Survival at Study Day 30
Time frame: Day 30
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
Time frame: One to forty-nine days
| Milestone | APX001 Treatment |
|---|---|
| Started | 21 |
| Completed | 20 |
| Not completed | 1 |
Treatment Success is defined as meeting all of the following criteria: Two consecutive blood cultures negative for Candida spp. Alive at EOST No concomitant use of any other systemic antifungal therapies through end of study treatment
| Participants | Treatment Period - MITT |
|---|---|
| Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC) | 16 |
Time to first negative blood culture was defined as the number of days from first dose date of study drug to the date of first post-Baseline negative blood culture + 1. Patients without a negative blood culture at post-Baseline visits were censored at the last assessment date.
| Days | MITT Population |
|---|---|
| Time to First Negative Blood Culture | 2.4 ± 1.13 |
| Participants | EOST (End of Study Drug Treatment) | EOT (End of Antifungal Treatment) | Follow-up 2 Weeks After EOT | Follow-up 4 Weeks After EOT |
|---|---|---|---|---|
| Percentage of Patients With Mycological Outcomes at End of Study Treatment (EOST), End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT) | 16 | 15 | 1 | 0 |
| percentage of participants | Treatment Success 2 Weeks After EOT | Treatment Success 4 Weeks After EOT |
|---|---|---|
| Percentage of Patients With Treatment Success at End of Treatment (EOT), and 2 and 4 Weeks After End of Treatment (EOT) | 60.0 | 55.0 |
| Participants | MITT Population |
|---|---|
| Overall Survival at Study Day 30 | 17 |
| Participants | Safety Population |
|---|---|
| Number of Patients With Treatment Emergent Adverse Events (TEAEs) | 20 |
Collected over One to forty-nine days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Population | 5/21 (23.8%) | 9/21 (42.9%) | 20/21 (95.2%) |
| Event | Safety Population |
|---|---|
| Septic shockInfections and infestations | 2/21 |
| BacteraemiaInfections and infestations | 1/21 |
| Bacterial sepsisInfections and infestations | 1/21 |
| Enterobacter sepsisInfections and infestations | 1/21 |
| Necrotising fasciitisInfections and infestations | 1/21 |
| SepsisInfections and infestations | 1/21 |
| Stenotrophomonas sepsisInfections and infestations | 1/21 |
| Systemic candidaInfections and infestations | 1/21 |
| Urinary tract infection bacterialInfections and infestations | 1/21 |
| Cardiac failure congestiveCardiac disorders | 1/21 |
| Event | Safety Population |
|---|---|
| DiarrhoeaGastrointestinal disorders | 3/21 |
| VomitingGastrointestinal disorders | 3/21 |
| Oedema peripheralGeneral disorders | 3/21 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/21 |
| BacteraemiaInfections and infestations | 2/21 |
| Septic shockInfections and infestations | 2/21 |
| NauseaGastrointestinal disorders | 2/21 |
| PyrexiaGeneral disorders | 2/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/21 |
| Acute kidney injuryRenal and urinary disorders | 2/21 |
Treatment Period - MITT
| Age, Categorical(Participants) | Treatment Period - MITT |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 10 |
| Sex: Female, Male(Participants) | Treatment Period - MITT |
|---|---|
| Female | 7 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Period - MITT |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Treatment Period - MITT |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Treatment Period - MITT |
|---|---|
| Belgium | 7 |
| United States | 3 |
| Israel | 9 |
| Spain | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Mar 2020, 17 months.
Results were first posted in Aug 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fosmanogepix